Yarrow Bioscience (NASDAQ:YARW) Short Interest Update

Yarrow Bioscience (NASDAQ:YARW) was the target of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 19,427 shares, a growth of 54.4% from the July 30th total of 12,582 shares. Based on an average daily trading volume, of 17,382 shares, the short-interest ratio is presently 1.1 days. Currently, 0.8% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Several analysts have commented on YARW shares. BTIG Research assumed coverage on shares of Yarrow Bioscience in a research note on Monday, August 3rd. They set a “buy” rating and a $58.00 price objective for the company. Wall Street Zen raised shares of Yarrow Bioscience to a “hold” rating in a research note on Saturday, August 22nd. Finally, TD Cowen initiated coverage on Yarrow Bioscience in a report on Tuesday, July 28th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $58.00.

Yarrow Bioscience Stock Down 0.3%

NASDAQ YARW traded down $0.09 on Tuesday, reaching $32.88. The stock had a trading volume of 3,577 shares, compared to its average volume of 13,762. Yarrow Bioscience has a 12-month low of $14.02 and a 12-month high of $46.95. The firm has a market cap of $87.78 million, a price-to-earnings ratio of -2.25 and a beta of 1.96.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.